Share on StockTwits

Cytosorbents Corp (NASDAQ:CTSO) Director Al Kraus sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $0.24, for a total transaction of $12,000.00. Following the transaction, the director now directly owns 1,393,631 shares in the company, valued at approximately $334,471. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Cytosorbents Corp (NASDAQ:CTSO) remained flat at $0.24 during trading on Friday. The stock had a trading volume of 147,515 shares. Cytosorbents Corp has a 52 week low of $0.08 and a 52 week high of $0.35. The stock has a 50-day moving average of $0.23 and a 200-day moving average of $0.21. The company’s market cap is $72.2 million.

Cytosorbents Corp (NASDAQ:CTSO) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). On average, analysts predict that Cytosorbents Corp will post $-0.02 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on CTSO shares. Analysts at Zacks reiterated an “outperform” rating on shares of Cytosorbents Corp in a research note on Friday, May 16th. They now have a $0.50 price target on the stock. Finally, analysts at Brean Capital raised their price target on shares of Cytosorbents Corp from $0.50 to $1.00 in a research note on Tuesday, April 1st. They now have a “buy” rating on the stock.

CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.